Study of ONO-7579 in Patients With Advanced Solid Tumors/ NTRK Gene Fusion Positive Advanced Solid Tumors (ONTRK)
An Open-label, Multi-center, Dose-escalation and Expansion Study to Evaluate the Safety and Efficacy of ONO-7579 in Patients With Advanced Solid Tumors/ NTRK Gene Fusion Positive Advanced Solid Tumors
Sponsor: Ono Pharmaceutical Co. Ltd
Terminated
The study was stopped for commercial reasons. No safety issues were reported.
Other terminated trials from Ono Pharmaceutical Co. Ltd
- Solid Tumor · Phase PHASE1 · Feb 2025
- Acute Leukemia · Phase PHASE1/PHASE2 · Jan 2023
- Acromegaly · Phase PHASE1 · May 2019
- Osteoarthritis, Knee · Phase PHASE2 · Jan 2018
- Healthy Adult Subjects · Phase PHASE1
More terminations from Ono Pharmaceutical Co. Ltd
A PHASE1 clinical study on Solid Tumor, this trial is terminated or withdrawn. The trial is conducted by Ono Pharmaceutical Co. Ltd and has accumulated 9 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Oct 2019 — Jan 2021 [monthly]
Terminated PHASE1
Phase: PHASE1_PHASE2 → PHASE1
-
Jun 2018 — Oct 2019 [monthly]
Terminated PHASE1_PHASE2
▶ Show 4 earlier versions
-
Mar 2018 — Jun 2018 [monthly]
Terminated PHASE1_PHASE2
Status: Active Not Recruiting → Terminated
-
Feb 2018 — Mar 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Oct 2017 — Feb 2018 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2017 — Oct 2017 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Ono Pharmaceutical Co. Ltd
For direct contact, visit the study record on ClinicalTrials.gov .